Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO ‐incompatible hematopoietic stem cell transplant
Journal of Clinical Apheresis · 2023
DOI: 10.1002/jca.22041 ↗At a glance
Fallbericht in Journal of Clinical Apheresis, 2023. Written by Angelica Vivero and 3 co-authors. Institution: Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Red-Cell Aplasia, Pure. Cited 6 times so far (Crossref); 11 references.
Abstract (original language)
Hematopoietic stem cell transplants (HSCTs) are widely used in the treatment of hematologic malignancies and bone marrow failure syndromes. ABO compatibility is typically of secondary importance, and up to 50% of HSCT are performed in ABO‐incompatible pairings. In the literature, pure red cell aplasia (PRCA) occurs in 1% to 50% of all major/bidirectional ABO‐incompatible stem cell transplants, but treatment of PRCA remains heterogeneous. Here, we report two cases in which patients with transfusion‐dependent PRCA following HSCT were successfully treated with therapeutic plasma exchange (TPE). Case 1: A 52‐year‐old type O‐positive male with acute myeloid leukemia underwent HSCT using apheresis‐derived HSCs from a fully human leukocyte antigen (HLA)‐matched, related type A‐positive male donor. He developed PRCA that was refractory to multiple therapies, so a series of 10 TPE was performed over 3 weeks. Case 2: A 21‐year‐old type A‐positive male with aplastic anemia underwent HSCT using bone marrow‐derived HSCs from a fully HLA‐matched related type B‐positive female donor. He developed PRCA that was refractory to multiple therapies, so a series of 5 TPE was performed over 2 weeks. Case 1: The patient has been transfusion independent since TPE #7, and type A red blood cells (RBCs) were seen on the ABO type after TPE #9. Case 2: The patient has been transfusion independent since after TPE #1, and type B RBCs were seen on the ABO type after TPE #5. TPE was successful in treating two patients with PRCA after ABO‐incompatible HSCT transplants. Isoagglutinin titers decreased below the level of detection for both our patients. Ultimately both patients became transfusion independent and showed evidence of erythroid cell recovery.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
- Department of Pathology, Cooper University Health Care, Camden, New Jersey, USA.
ORCID profiles: Angelica Vivero, Alexis R Peedin, Julie Katz Karp
Cite
APA
Vivero, A., Peedin, A. R., Gao, Y., & Karp, J. K. (2023). Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO ‐incompatible hematopoietic stem cell transplant. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22041
Vancouver
Vivero A, Peedin AR, Gao Y, Karp JK. Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO ‐incompatible hematopoietic stem cell transplant. Journal of Clinical Apheresis. 2023. doi:10.1002/jca.22041
BibTeX
@article{Vivero2023,
author = {Vivero, Angelica and Peedin, Alexis R and Gao, Yuanzheng and Karp, Julie Katz},
title = {Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO ‐incompatible hematopoietic stem cell transplant},
journal = {Journal of Clinical Apheresis},
year = {2023},
doi = {10.1002/jca.22041}
}
EUVIMED